> Research Use Only Disclaimer: BPC-157, TB-500 (Thymosin Beta-4), KPV, and GHK-Cu are research peptides not approved by the FDA for human therapeutic use. All information on this page is provided for educational and informational purposes only. This guide does not constitute medical advice, diagnosis, or treatment. Do not administer these compounds to humans or animals outside of appropriately supervised research settings with proper institutional oversight and regulatory compliance.
---
Introduction: The Case for a Complete Recovery Stack
In the landscape of peptide research, four compounds have emerged as the most-studied combination for tissue repair, gut healing, and systemic recovery: BPC-157, TB-500 (Thymosin Beta-4), KPV, and GHK-Cu. When examined individually, each compound demonstrates compelling evidence across a range of repair pathways. When combined, researchers hypothesize that their mechanisms are additive — possibly synergistic — covering the full cascade of tissue repair from initial injury through matrix remodeling.
This rationale has driven market behavior. Across the peptides.so database, this 4-compound combination appears in over 78 active supplier listings, making it the highest-listed combination product in the catalog. Researchers sourcing these compounds together are looking for protocols, not just individual peptide profiles. This guide addresses that gap.
The four compounds work at distinct but interconnected biological levels:
- •BPC-157 acts as a gut-brain axis modulator and systemic tissue repair catalyst, primarily through nitric oxide signaling and vascular endothelial growth factor (VEGF) upregulation.
- •TB-500 (Thymosin Beta-4) mobilizes progenitor cells and promotes systemic angiogenesis through actin dynamics and integrin-linked kinase (ILK) activation.
- •KPV is a potent anti-inflammatory tripeptide targeting NF-κB — the master regulator of the inflammatory response — with particular efficacy in gut epithelium models.
- •GHK-Cu drives the remodeling phase of tissue repair by modulating collagen and elastin synthesis, promoting angiogenesis, and influencing the expression of over 1,000 genes involved in tissue homeostasis.
Together, these four compounds address every major phase of tissue repair: acute inflammation resolution, cell migration and proliferation, vascularization, and extracellular matrix remodeling. No single compound in this stack meaningfully duplicates the mechanism of another — they are complementary, not redundant.
This guide covers individual compound summaries, the rationale for their combination, proposed synergistic mechanisms, research protocol frameworks for each compound, and sourcing guidance. All citations have been verified against PubMed.
---
Individual Compound Summaries
BPC-157 (Body Protection Compound-157)
BPC-157 is a synthetic 15-amino acid peptide derived from a partial sequence of human gastric juice protein (Body Protection Compound). It has been extensively studied in rodent models of gastrointestinal injury, tendon and ligament damage, bone healing, and neurological insult. Its primary mechanisms involve upregulation of vascular endothelial growth factor (VEGF), nitric oxide (NO) system modulation, and direct influence on growth factor receptor signaling including EGF and FGFR2.
Research has established that BPC-157 exerts effects that appear beyond its primary site of administration. Systemic administration in animal models produces healing effects in both gastrointestinal and musculoskeletal tissue. Studies have demonstrated accelerated tendon-to-bone healing, enhanced muscle repair following corticosteroid-induced injury, and protection of intestinal epithelium in colitis models (Sikiric P, et al. Curr Pharm Des. 2018; Chang CH, et al. J Appl Physiol. 2011).
For the purposes of this stack, BPC-157 serves as the local-to-systemic bridge — initiating vascular and growth factor cascades that amplify the effects of the other three compounds.
---
TB-500 (Thymosin Beta-4 Synthetic Analog)
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein ubiquitously expressed in mammalian tissues. The active fragment of Tβ4 used in most research (the LKKTETQ sequence) is responsible for its biological activity, and TB-500 is designed to deliver this activity in a more concentrated, research-grade form.
Tβ4's primary function is as a G-actin sequestering protein — it binds and sequesters G-actin monomers, regulating the actin polymerization dynamics that govern cell motility and migration. Beyond actin regulation, TB-500 activates integrin-linked kinase (ILK), promotes stem and progenitor cell mobilization from bone marrow niches, and stimulates the formation of new blood vessels through VEGF and other angiogenic pathways (Bock-Marquette I, et al. Nature. 2004; Smart N, et al. Nature. 2007).
TB-500's systemic distribution pattern — it circulates broadly after administration — makes it uniquely suited to address healing at sites distal from the injection point. In this stack, TB-500 provides the systemic vascular scaffolding that supports tissue ingrowth and progenitor cell recruitment across multiple injury sites simultaneously.
---
KPV (Lys-Pro-Val)
KPV is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), consisting of the amino acid sequence Lysine-Proline-Valine. Despite its minimal size (three amino acids), KPV demonstrates remarkable anti-inflammatory potency in research settings, particularly in models of intestinal inflammation, dermatitis, and sepsis-associated cytokine storm.
KPV's mechanism involves both melanocortin receptor 1 (MC1R)-dependent and MC1R-independent pathways. Its primary downstream target is NF-κB — the nuclear transcription factor that controls expression of pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and IL-8. By suppressing NF-κB activation, KPV reduces the inflammatory cascade at its source rather than blocking individual downstream mediators (Kanwar JR, et al. Clin Exp Pharmacol Physiol. 2009;.
Critically for gut research, KPV maintains its anti-inflammatory activity when delivered orally in nanoparticle formulations — a finding that has made it particularly valuable in intestinal epithelium repair models. In this stack, KPV acts as the inflammation resolution master switch, reducing the acute cytokine burden that can impair the healing effects of the other compounds.
---
GHK-Cu (Glycine-Histidine-Lysine Copper Complex)
GHK-Cu is a naturally occurring tripeptide-copper complex first isolated from human plasma in the 1970s. It is found in multiple body fluids (plasma, saliva, urine) and its serum concentration declines with age — from approximately 200 ng/mL in youth to 80 ng/mL by age 60. This age-related decline has made it a focus of anti-aging and regenerative research.
GHK-Cu's biological activity is unusually broad for a tripeptide. Research has demonstrated its influence on collagen synthesis, matrix metalloproteinase (MMP) regulation, angiogenesis, antioxidant response, and gene expression. Microarray analysis has revealed that GHK-Cu modulates the expression of over 1,000 human genes, with a pronounced effect on genes involved in tissue remodeling, skin repair, and immune regulation (Pickart L, Margolina A. Int J Mol Sci. 2018;.
In the context of tissue repair, GHK-Cu drives what researchers call the quality phase — not just restoring tissue, but restoring tissue architecture. It activates TGF-β1 signaling to drive collagen and elastin synthesis, while simultaneously activating MMP-2 to remodel disorganized scar tissue. This dual activity — building and remodeling — is what distinguishes GHK-Cu's contribution to this stack from simple growth factor stimulation.
---
Why Combine All Four? The Synergistic Rationale
Each of the four compounds addresses a distinct bottleneck in the tissue repair cascade. Understanding why they are combined requires understanding the phases of healing and where each compound's mechanism is most active.
The Three Phases of Tissue Repair — and How the Stack Aligns
Phase 1: Inflammatory Phase (Hours to Days)
- •Damaged tissue signals for immune cell infiltration
- •Neutrophils and macrophages clear debris and pathogens
- •Pro-inflammatory cytokines peak (TNF-α, IL-1β, IL-6)
- •If dysregulated: chronic inflammation impairs healing
Stack activity in Phase 1: KPV suppresses NF-κB-driven cytokine overproduction. BPC-157 protects vascular integrity and prevents excessive permeability. Together, they control the amplitude of inflammation without suppressing the necessary immune response entirely.
Phase 2: Proliferative Phase (Days to Weeks)
- •Fibroblast migration and proliferation
- •New blood vessel formation (angiogenesis)
- •Provisional matrix deposition (fibronectin, early collagen)
- •Epithelial cell migration to close wounds
Stack activity in Phase 2: TB-500 mobilizes progenitor cells and promotes angiogenesis to vascularize the provisional matrix. BPC-157 continues to upregulate VEGF and drive fibroblast recruitment. The two compounds work synergistically here — TB-500 provides the cells and vascular scaffold; BPC-157 sustains the growth factor environment.
Phase 3: Remodeling Phase (Weeks to Months)
- •Type III collagen replaced with organized Type I collagen
- •Tissue tensile strength increases
- •Scar tissue matures and contracts
- •Final vascular normalization
Stack activity in Phase 3: GHK-Cu drives collagen type switching and MMP-mediated remodeling. It activates TGF-β1 to promote mature collagen synthesis while simultaneously preventing excessive fibrosis. This phase determines whether the repaired tissue is functional or scarred — GHK-Cu is the primary driver of quality outcomes.
The Gut-Systemic Axis: A Unique Strength of This Combination
This stack has a particular advantage in gut research models because three of the four compounds (BPC-157, KPV, and GHK-Cu) have demonstrated direct activity in gastrointestinal epithelium. BPC-157 is derived from gastric juice protein and has well-documented effects in inflammatory bowel disease models. KPV has been shown to reduce intestinal permeability and suppress mucosal inflammation. GHK-Cu promotes gut epithelial cell proliferation and modulates mucosal immune responses.
TB-500's systemic distribution means it can simultaneously address any musculoskeletal or cardiovascular tissue damage that may accompany systemic inflammatory states — covering the whole-body impact of gut dysfunction that often extends beyond the gastrointestinal tract.
No Meaningful Mechanism Overlap
A critical consideration in any compound stack is whether the components duplicate each other's effects — creating redundancy rather than synergy. Analysis of each compound's primary molecular targets reveals minimal overlap:
| Compound | Primary Target | Primary Pathway |
|---|---|---|
| BPC-157 | VEGF, NO system | Vascularization, GI protection |
| TB-500 | G-actin, ILK | Cell mobility, angiogenesis |
| KPV | NF-κB, MC1R | Inflammation resolution |
| GHK-Cu | TGF-β1, MMP-2 | Matrix remodeling, collagen |
No two compounds target the same primary mechanism. This is what makes this combination theoretically compelling: each compound contributes something the others cannot.
---
Synergistic Mechanisms — Research Evidence
BPC-157 + TB-500: The Foundation Pair
The BPC-157 + TB-500 pairing is the most extensively studied combination in this stack, with the rationale well-established in the research community. BPC-157 operates through local tissue repair mechanisms — angiogenesis via VEGF, fibroblast recruitment, and NO-mediated vascular protection — while TB-500 provides a systemic layer through progenitor cell mobilization and widespread actin-mediated cell motility.
The key synergy between these two compounds lies in their complementary approaches to vascularization. BPC-157 promotes local VEGF upregulation to drive neovascularization at the injury site; TB-500 mobilizes circulating endothelial progenitor cells that are then recruited to that site. In animal models, combined administration of these compounds has been reported to produce faster and more complete vascularization than either compound alone, though controlled head-to-head studies in this specific area remain limited (Goldstein AL, Hannappel E, Kleinman HK. Trends Mol Med. 2005;.
TB-500's actin-sequestering activity also facilitates the cell migration that BPC-157-induced growth factor signals require. VEGF upregulation recruits endothelial cells to form new capillaries — but those cells must migrate to the injury site. TB-500's enhancement of actin dynamics is precisely what enables that migration. The growth factor signal (BPC-157) and the cell motility mechanism (TB-500) are, by design, complementary.
BPC-157 + KPV: Gut Epithelium Partnership
In gut research models, the BPC-157 + KPV combination addresses two distinct but related problems: chronic mucosal inflammation and impaired epithelial barrier function.
KPV's NF-κB suppression reduces the cytokine storm that drives mucosal damage — TNF-α, IL-1β, and IL-6 levels are all reduced in KPV-treated intestinal epithelium models. But NF-κB suppression alone does not regenerate damaged tissue; it stops destruction but does not drive repair. This is where BPC-157 adds critical value. Its VEGF upregulation promotes the vascular supply that regenerating epithelium requires, while its direct effects on gut epithelial cell proliferation drive mucosal restoration (Sikiric P, et al. Curr Pharm Des. 2018).
The result of this pairing, in research terms, is a simultaneous reduction of the inflammatory load that prevents healing and an active promotion of the regenerative signaling required to replace damaged mucosa. Researchers studying inflammatory bowel disease models have used variations of this approach to distinguish anti-inflammatory effects from pro-regenerative effects in mucosal healing.
GHK-Cu + the Triad: The Remodeling Layer
GHK-Cu's contribution to this stack is temporally distinct from the other three compounds. While BPC-157, TB-500, and KPV are most active during the acute and proliferative phases of repair, GHK-Cu's primary value emerges during remodeling — typically weeks 3 through 12 of a healing protocol.
The collagen-remodeling activity of GHK-Cu (activation of MMP-2 and TGF-β1) produces quantifiably different tissue quality than repair without GHK-Cu intervention. In research models examining cutaneous wound healing, GHK-Cu-treated tissue shows improved collagen bundle organization, greater tensile strength, and reduced scar formation compared to controls — not because it speeds repair, but because it improves the architectural quality of the repaired tissue (Pickart L, Margolina A. Int J Mol Sci. 2018;.
When added to a foundation of BPC-157, TB-500, and KPV, GHK-Cu receives a well-vascularized, inflammation-resolved tissue environment in which to conduct this remodeling work. The other three compounds effectively prepare the substrate for GHK-Cu's quality-driving activity. This is the mechanistic logic of phase sequencing in this stack.
The Full Four-Compound Matrix
When all four compounds are active simultaneously, the cumulative mechanism coverage becomes:
1. Inflammation control (KPV → NF-κB suppression)
2. Local vascularization (BPC-157 → VEGF upregulation)
3. Systemic progenitor recruitment (TB-500 → ILK/actin/cell mobilization)
4. Angiogenic scaffold formation (TB-500 + BPC-157 → endothelial cell migration)
5. Epithelial barrier restoration (BPC-157 + KPV → mucosal repair)
6. Matrix deposition (BPC-157 → fibroblast recruitment)
7. Collagen quality remodeling (GHK-Cu → TGF-β1 + MMP-2)
8. Gene expression optimization (GHK-Cu → 1,000+ gene modulation)
No single compound in isolation can address all eight. The stack provides coverage at every level of the repair cascade.
---
Research Protocols
The following protocols are based on published research data and commonly reported experimental frameworks. They represent typical ranges used in animal model studies and are presented strictly for research reference purposes.
> Important: These are research protocols derived from animal model literature. They do not constitute dosing recommendations for human use. All concentrations and volumes described assume use in appropriately supervised research settings.
BPC-157 Research Protocol
Standard research dose range: 200–500 mcg/day (2–5 mcg/kg for a 100g rodent model; scaled proportionally for larger models)
Administration routes studied:
- •Subcutaneous (SQ): Most common in systemic injury models. Standard injection site rotation.
- •Intraperitoneal (IP): Common in gastrointestinal research models for direct abdominal delivery.
- •Oral: Shown effective in GI models, including colitis. Less consistent bioavailability for non-GI endpoints.
Reconstitution protocol:
- •Supplied as lyophilized powder, typically 2 mg or 5 mg per vial
- •Reconstitute with bacteriostatic water (0.9% benzyl alcohol)
- •Add diluent slowly by directing against the glass wall — do not shake
- •Standard reconstitution for a 5 mg vial: 2.5 mL bacteriostatic water → 2 mg/mL concentration
- •For a 250 mcg dose: draw 0.125 mL (125 µL)
- •Store reconstituted peptide at 2–8°C; use within 30 days
Typical research schedule: Daily administration, 5–7 days per week, for 4–12 weeks depending on model
Key studies:
- •Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2018;24(18):1938-1956.
- •Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-780.
- •Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Med Sci Monit. 2010;16(3):BR81-88.
---
TB-500 Research Protocol
Standard research dose range: 2–5 mg per administration (loading phase); 1–2 mg (maintenance)
Administration routes studied:
- •Subcutaneous (SQ): Most commonly used; allows consistent bioavailability
- •Intravenous (IV): Used in cardiac repair models for faster distribution
Reconstitution protocol:
- •Supplied as lyophilized powder, typically 5 mg or 10 mg per vial
- •Reconstitute with bacteriostatic water
- •For a 5 mg vial with 2.5 mL diluent: 2 mg/mL concentration
- •For a 2 mg dose: draw 1.0 mL (1,000 µL)
- •Store reconstituted peptide at 2–8°C; use within 30 days
Loading/maintenance framework (based on published research):
- •Loading phase (Weeks 1–4): 2–4 mg administered 2× per week (Monday/Thursday)
- •Maintenance phase (Weeks 5–12): 2–4 mg administered 1× per week
Key studies:
- •Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-182.
- •Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-472.
- •Goldstein AL, Hannappel E, Kleinman HK. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-429.
---
KPV Research Protocol
Standard research dose range: 0.1–1.0 mg/day, dose-dependent effects reported in intestinal models
Administration routes studied:
- •Oral (encapsulated nanoparticle formulations): Effective in murine colitis models; standard nanoparticle delivery maintains GI-targeted activity
- •Subcutaneous (SQ): Used in systemic inflammation models
- •Topical: Used in dermatitis and skin wound models
Reconstitution protocol:
- •Supplied as lyophilized powder, typically 1 mg or 5 mg per vial
- •Reconstitute with sterile water or bacteriostatic water
- •Standard: 1 mg vial + 1.0 mL diluent = 1 mg/mL
- •For 0.5 mg dose: draw 0.5 mL (500 µL)
- •Highly water-soluble; reconstitutes easily at room temperature
- •Store at 2–8°C after reconstitution; use within 21 days
Typical research schedule: Daily administration in acute models; 5-day-on/2-day-off in extended protocols
Key studies:
- •Gonindard C, et al. "α-MSH C-terminal tripeptide modulates inflammatory responses in TNBS colitis." Regul Pept. 2009; PMID 19761804.
---
GHK-Cu Research Protocol
Standard research dose range: 1–3 mg per administration (systemic); 0.1–0.5% concentration (topical)
Administration routes studied:
- •Subcutaneous (SQ): Most studied for systemic tissue repair effects
- •Topical: Established route for skin, wound, and dermal repair models
- •Intradermal: Used in hair follicle research models
Reconstitution protocol:
- •Supplied as lyophilized powder or pre-made copper complex
- •Reconstitute lyophilized GHK-Cu with sterile water
- •Standard: 5 mg vial + 2.5 mL diluent = 2 mg/mL
- •For a 1 mg dose: draw 0.5 mL (500 µL)
- •Stable in solution; blue color indicates copper coordination is intact
- •Store at 2–8°C; use within 30 days
Typical research schedule (systemic): 2–3× per week administration; consistent with tissue remodeling timescales (weeks, not days)
Key studies:
- •Maquart FX, et al. "Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+." FEBS Lett. 1988;238(2):343-346. PMID 3169264.
---
Complete 12-Week Protocol Framework
The following phased protocol framework integrates all four compounds based on their phase-specific mechanisms. This is a research model framework — not a clinical recommendation.
Phase 1: Acute Intervention (Weeks 1–4)
The first phase prioritizes inflammation control and early vascularization. All four compounds are active, but KPV and BPC-157 do the heaviest lifting.
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| BPC-157 | 250–500 mcg | Daily | SQ or IP |
| TB-500 | 2–4 mg | 2× per week | SQ |
| KPV | 0.5–1.0 mg | Daily | SQ or oral |
| GHK-Cu | 1–2 mg | 3× per week | SQ |
Rationale: BPC-157 and KPV address the acute inflammatory environment simultaneously. TB-500 loading doses establish the angiogenic progenitor pool. GHK-Cu begins its gene-expression modulation — its effects on collagen gene upregulation start early even though they manifest later.
Phase 2: Active Recovery (Weeks 5–8)
Inflammation has been controlled; the proliferative phase is underway. TB-500 transitions to maintenance. BPC-157 continues daily. KPV frequency may reduce.
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| BPC-157 | 250 mcg | Daily | SQ |
| TB-500 | 2–4 mg | 1× per week | SQ |
| KPV | 0.5 mg | 5×/week or every other day | SQ |
| GHK-Cu | 2–3 mg | 3× per week | SQ |
Rationale: BPC-157 maintains the growth factor environment during fibroblast proliferation and matrix deposition. TB-500 maintenance continues systemic progenitor support. GHK-Cu dose increases as the remodeling phase intensifies — collagen synthesis peaks between weeks 4–8.
Phase 3: Remodeling and Taper (Weeks 9–12)
The acute injury environment has resolved. The primary activity is collagen maturation and quality remodeling. GHK-Cu remains active; BPC-157 tapers; KPV and TB-500 transition to minimal maintenance.
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| BPC-157 | 250 mcg | 5×/week | SQ |
| TB-500 | 2 mg | Every 2 weeks | SQ |
| KPV | 0.5 mg | 3×/week | SQ (or discontinue at week 10) |
| GHK-Cu | 2–3 mg | 3× per week | SQ or topical at site |
Rationale: GHK-Cu is doing the quality work in this phase — collagen cross-linking, MMP-mediated remodeling, and tensile strength improvement. BPC-157 continues supporting vascular integrity. TB-500 and KPV are tapered as their phase-specific demands diminish.
---
Compound Compatibility and Storage Considerations
A critical practical question for researchers running multi-compound protocols is whether these compounds can be co-administered or must be given separately.
Can These Compounds Be Mixed in a Single Syringe?
The short answer, based on available research on peptide stability, is no — they should not be mixed. Several considerations:
- •Physicochemical incompatibility risk: Peptides at different pH optima can precipitate or degrade when combined. BPC-157 and TB-500 have not been formally tested for stability when combined in a single solution.
- •Copper chelation interference: GHK-Cu contains a coordinated copper ion. Other peptides in the same solution could potentially disrupt copper coordination or be modified by the copper complex.
- •Research reproducibility: Separate administration preserves the ability to attribute specific effects to individual compounds — a core requirement of well-designed research protocols.
Recommended approach: Prepare each compound separately in its own syringe, administered at distinct injection sites or with minimal time separation between administrations.
Storage Protocols
| Compound | Lyophilized Storage | Reconstituted Storage | Stability (Reconstituted) |
|---|---|---|---|
| BPC-157 | -20°C, desiccated | 2–8°C | ~30 days |
| TB-500 | -20°C, desiccated | 2–8°C | ~30 days |
| KPV | -20°C, desiccated | 2–8°C | ~21 days |
| GHK-Cu | -20°C, desiccated | 2–8°C | ~30 days |
All compounds should be protected from light and freeze-thaw cycling. Multiple freeze-thaw cycles have been shown to degrade peptide integrity, particularly for larger peptides like TB-500.
---
Sourcing Guidance
The quality of research outcomes using this stack depends directly on the purity and documentation standards of the compounds sourced. When evaluating suppliers for this 4-compound combination, the following documentation should be standard requirements for any research program.
Minimum Documentation Requirements
- •HPLC purity certificate: ≥98% purity for each compound, verified by an independent third-party laboratory
- •Mass spectrometry (MS) confirmation: Molecular weight match confirming correct peptide sequence
- •Endotoxin testing: Critical for any in vivo administration; endotoxin contamination can confound inflammation endpoint measurements
- •Certificate of Analysis (CoA): Batch-specific, not generic
Suppliers offering this documentation transparently represent the baseline standard for research-grade procurement.
Compare Prices and Sources
Peptides.so maintains actively updated supplier comparison pages for each compound in this stack. Use these to compare pricing, purity documentation, and shipping policies across vetted suppliers:
- •BPC-157 supplier comparison: /peptide/bpc-157
- •TB-500 supplier comparison: /peptide/tb-500
- •GHK-Cu supplier comparison: /peptide/ghk-cu
For real-time price tracking and per-milligram cost calculations across multiple suppliers, the Peptide Calculator tool allows researchers to compare effective cost at specific dose points — accounting for vial size, concentration, and target research dose.
Individual Compound Guides
For detailed sourcing guidance on each compound, including supplier quality analysis and pricing breakdowns:
- •BPC-157 Dosage & Research Protocol Guide 2026
- •GHK-Cu Copper Peptide Dosage & Application Guide 2026
---
Research Budget Framework
Budgeting for a 12-week 4-compound protocol requires accounting for significantly different dose magnitudes across compounds. KPV and GHK-Cu are dosed in the milligram range; BPC-157 in the microgram range.
Estimated Research Supply for a 12-Week Protocol
| Compound | Total Dose Required (12 weeks) | Typical Vial Sizes | Estimated Vials Needed |
|---|---|---|---|
| BPC-157 | ~300 mcg/day × 84 days ≈ 25 mg | 5 mg, 10 mg | 3 × 10 mg vials |
| TB-500 | Loading 4 mg × 8 doses + Maint 2 mg × 6 doses ≈ 44 mg | 5 mg, 10 mg | 5 × 10 mg vials |
| KPV | 0.5 mg/day × 60 days + 0.5 mg × 3×/wk × 4 wks ≈ 36 mg | 5 mg, 10 mg | 4 × 10 mg vials |
| GHK-Cu | 2 mg × 3×/wk × 12 wks ≈ 72 mg | 5 mg, 10 mg | 8 × 10 mg vials |
Note: These estimates assume a single research subject. Actual quantities should be calculated based on the specific research model's weight-based dosing if applicable.
GHK-Cu requires the most volume due to its higher dose and three-times-per-week frequency. TB-500's loading phase front-loads the cost in the first four weeks. BPC-157, despite daily administration, requires the least total mass due to its microgram-level dosing.
---
Frequently Asked Questions
Q: Is there peer-reviewed research specifically studying the BPC-157 + TB-500 + KPV + GHK-Cu combination?
A: To our knowledge, no peer-reviewed publications have examined this exact 4-compound combination in a single experimental design. The stack rationale is built from extensive individual compound research and the well-documented BPC-157 + TB-500 pairing. The theoretical basis for adding KPV (NF-κB anti-inflammatory coverage) and GHK-Cu (remodeling quality) is grounded in their independently documented mechanisms, but formal combination studies would be needed to confirm specific synergistic effects.
Q: Is this stack primarily for gut healing or musculoskeletal repair?
A: This stack is uniquely positioned to support both simultaneously. BPC-157 and KPV have their strongest evidence base in gastrointestinal models. TB-500 and BPC-157 together have the most evidence in musculoskeletal models. GHK-Cu spans both domains — it was originally studied in wound healing and skin repair but has broader tissue remodeling applications. Researchers studying systemic recovery protocols involving both gut and musculoskeletal components may find this the most comprehensive option.
Q: Can all four compounds be administered at the same time of day?
A: There is no published evidence of pharmacokinetic interactions that would require time-separated dosing. However, as noted in the compatibility section above, they should be administered from separate syringes. Administering them in sequence (with brief intervals between injections) on the same schedule is the common approach in research protocols combining multiple peptides.
Q: What order should compounds be given during a single session?
A: No established protocol defines an optimal order. In practice, most research protocols administer each compound at a separate injection site sequentially. A practical approach: BPC-157 (smallest volume/dose), then KPV, then GHK-Cu, then TB-500 (largest volume). This allows each compound to begin local distribution before the next is administered.
Q: How does this stack compare to the BPC-157 + TB-500 two-compound combination?
A: The 2-compound BPC-157 + TB-500 stack addresses acute repair and vascularization. Adding KPV specifically targets the inflammatory component — useful in research models where inflammation is a primary variable. Adding GHK-Cu addresses the remodeling phase, which is not directly targeted by either BPC-157 or TB-500 alone. Whether the 4-compound stack is appropriate versus the 2-compound version depends on the research question and the model being studied. For a broader recovery model or one involving gut-specific inflammation, the 4-compound protocol provides more comprehensive mechanism coverage. See our BPC-157 vs TB-500 research comparison guide for the 2-compound analysis.
Q: What purity standards should I require from suppliers for a stack protocol?
A: Minimum ≥98% HPLC purity for each compound, verified by an independent laboratory with batch-specific documentation. For protocols involving in vivo administration, endotoxin testing results should be included in the CoA. When running a multi-compound protocol, contamination in any single compound can confound results — stringent quality requirements apply to all four compounds, not just the primary peptide.
---
Internal Resources
Use these guides for individual compound deep-dives and sourcing comparisons:
- •BPC-157 Complete Research Guide 2026 — Full profile: mechanisms, GI and musculoskeletal applications, sourcing
- •BPC-157 Dosage & Research Protocol Guide 2026 — Reconstitution, administration routes, dose ranges
- •BPC-157 + TB-500 Stack Protocol Guide 2026 — The 2-compound foundation of this stack, with detailed phase structure
- •GHK-Cu Dosage & Application Guide 2026 — Topical vs systemic protocols, reconstitution, sourcing
- •Peptide Calculator — Calculate doses, vial quantities, and per-milligram costs
---
Sources
1. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2018;24(18):1938-1956.
2. Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-780.
3. Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Med Sci Monit. 2010;16(3):BR81-88.
4. Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-182.
5. Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-472.
6. Maquart FX, et al. "Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+." FEBS Lett. 1988;238(2):343-346. PMID 3169264.
---
> Research Use Only Disclaimer: These compounds are sold for research purposes only. Not for human consumption. Not FDA-approved for therapeutic use. All research involving BPC-157, TB-500, KPV, and GHK-Cu must be conducted in accordance with applicable institutional and regulatory guidelines. The information in this guide is for educational purposes and does not constitute medical advice. Consult a qualified medical professional before considering any therapeutic application.